113 related articles for article (PubMed ID: 23135199)
1. Denosumab may reduce hypercalcaemia after transplantation for osteopetrosis.
BMJ; 2012 Nov; 345():e7477. PubMed ID: 23135199
[No Abstract] [Full Text] [Related]
2. Denosumab for post-transplantation hypercalcemia in osteopetrosis.
Shroff R; Beringer O; Rao K; Hofbauer LC; Schulz A
N Engl J Med; 2012 Nov; 367(18):1766-7. PubMed ID: 23113501
[No Abstract] [Full Text] [Related]
3. Resistant hypercalcaemia in metastatic parathyroid carcinoma.
Bowyer SE; White AM; Ransom DT; Davidson JA
Med J Aust; 2013 Jun; 198(10):559-61. PubMed ID: 23725272
[No Abstract] [Full Text] [Related]
4. Denosumab for the management of hypercalcemia of malignancy in patients with multiple myeloma and renal dysfunction.
Cicci JD; Buie L; Bates J; van Deventer H
Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):e207-11. PubMed ID: 25128013
[No Abstract] [Full Text] [Related]
5. Denosumab for tumor-induced hypercalcemia complicated by renal failure.
Bech A; de Boer H
Ann Intern Med; 2012 Jun; 156(12):906-7. PubMed ID: 22711097
[No Abstract] [Full Text] [Related]
6. Use of denosumab for renal cell carcinoma-associated malignant hypercalcemia: a case report and review of the literature.
Freeman A; El-Amm J; Aragon-Ching JB
Clin Genitourin Cancer; 2013 Dec; 11(4):e24-6. PubMed ID: 24007982
[No Abstract] [Full Text] [Related]
7. Letter to the editor: denosumab for “resistant” hypercalcemia in patients with impaired renal function.
Arampatzis S
J Clin Endocrinol Metab; 2015 Jan; 100(1):L6. PubMed ID: 25559545
[No Abstract] [Full Text] [Related]
8. Using denosumab to treat immobilization hypercalcemia in a post-acute care patient.
Booth KA; Hays CI
J Clin Endocrinol Metab; 2014 Oct; 99(10):3531-5. PubMed ID: 25033064
[TBL] [Abstract][Full Text] [Related]
9. Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy.
Adhikaree J; Newby Y; Sundar S
BMJ Case Rep; 2014 Jan; 2014():. PubMed ID: 24481018
[TBL] [Abstract][Full Text] [Related]
10. Resorptive hypercalcemia in post-essential thrombocythemia myelofibrosis: treatment with denosumab.
Khoury N; Chang J; Gru AA; Whyte MP
J Clin Endocrinol Metab; 2012 Sep; 97(9):3051-5. PubMed ID: 22730513
[TBL] [Abstract][Full Text] [Related]
11. Hematopoietic stem cell transplantation for infantile osteopetrosis.
Eapen M; Davies SM; Ramsay NK; Orchard PJ
Bone Marrow Transplant; 1998 Nov; 22(10):941-6. PubMed ID: 9849690
[TBL] [Abstract][Full Text] [Related]
12. Response letter to the editor.
Hu M
J Clin Endocrinol Metab; 2015 Jan; 100(1):L7. PubMed ID: 25559546
[No Abstract] [Full Text] [Related]
13. Bisphosphonate or RANK-L inhibitor for tumour-induced hypercalcaemia?
Bech A; Essink G; de Boer H
Neth J Med; 2012 Jun; 70(5):250-1. PubMed ID: 22744931
[No Abstract] [Full Text] [Related]
14. Denosumab for the treatment of bisphosphonate-refractory hypercalcemia.
Boikos SA; Hammers HJ
J Clin Oncol; 2012 Oct; 30(29):e299. PubMed ID: 22949145
[No Abstract] [Full Text] [Related]
15. Engraftment and survival following hematopoietic stem cell transplantation for osteopetrosis using a reduced intensity conditioning regimen.
Tolar J; Bonfim C; Grewal S; Orchard P
Bone Marrow Transplant; 2006 Dec; 38(12):783-7. PubMed ID: 17086207
[TBL] [Abstract][Full Text] [Related]
16. Characterization and management of hypercalcemia following transplantation for osteopetrosis.
Martinez C; Polgreen LE; DeFor TE; Kivisto T; Petryk A; Tolar J; Orchard PJ
Bone Marrow Transplant; 2010 May; 45(5):939-44. PubMed ID: 19802031
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcome of haematopoietic stem cell transplantation in autosomal recessive osteopetrosis: an EBMT report.
Driessen GJ; Gerritsen EJ; Fischer A; Fasth A; Hop WC; Veys P; Porta F; Cant A; Steward CG; Vossen JM; Uckan D; Friedrich W
Bone Marrow Transplant; 2003 Oct; 32(7):657-63. PubMed ID: 13130312
[TBL] [Abstract][Full Text] [Related]
18. Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone.
Gossai N; Hilgers MV; Polgreen LE; Greengard EG
Pediatr Blood Cancer; 2015 Jun; 62(6):1078-80. PubMed ID: 25556556
[TBL] [Abstract][Full Text] [Related]
19. Malignant osteopetrosis: hypercalcaemia after bone marrow transplantation.
Rawlinson PS; Green RH; Coggins AM; Boyle IT; Gibson BE
Arch Dis Child; 1991 May; 66(5):638-9. PubMed ID: 2039258
[TBL] [Abstract][Full Text] [Related]
20. The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction.
Goessl C; Katz L; Dougall WC; Kostenuik PJ; Zoog HB; Braun A; Dansey R; Wagman RB
Ann N Y Acad Sci; 2012 Aug; 1263():29-40. PubMed ID: 22831177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
